Cost-Utility Analysis of Robotic-Assisted Radical Cystectomy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21460%2F24%3A00376434" target="_blank" >RIV/68407700:21460/24:00376434 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1007/978-3-031-64636-2_1" target="_blank" >https://doi.org/10.1007/978-3-031-64636-2_1</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/978-3-031-64636-2_1" target="_blank" >10.1007/978-3-031-64636-2_1</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Cost-Utility Analysis of Robotic-Assisted Radical Cystectomy

Popis výsledku v původním jazyce

Bladder cancer is the second most common cancer of the urogenital tract. Radical cystectomy is the most reliable treatment method for infiltrating and aggressive tumors, and it can be performed using different surgical approaches. The aim of this study is to perform a clinical and economic evaluation and comparison of two surgical approaches to bladder cancer: robotic-assisted radical cystectomy (RARC) and open radical cystectomy (ORC). The study analysed direct medical costs from the perspective of both the healthcare payer and facility. It conducted a cost-utility analysis and presented the results as an incremental cost-utility ratio (ICUR) using quality-adjusted life-years (QALY). Uncertainty was assessed through one-way sensitivity analysis. The ICUR from the healthcare payer’s perspective is 1,485,211 CZK/QALY, and from the healthcare facility’s perspective, it is 1,186,048 CZK/QALY. The study indicates that RARC is not cost-effective for healthcare payers. The cost-effectiveness of healthcare facilities depends on the value of the willingness-to-pay threshold.

Název v anglickém jazyce

Cost-Utility Analysis of Robotic-Assisted Radical Cystectomy

Popis výsledku anglicky

Bladder cancer is the second most common cancer of the urogenital tract. Radical cystectomy is the most reliable treatment method for infiltrating and aggressive tumors, and it can be performed using different surgical approaches. The aim of this study is to perform a clinical and economic evaluation and comparison of two surgical approaches to bladder cancer: robotic-assisted radical cystectomy (RARC) and open radical cystectomy (ORC). The study analysed direct medical costs from the perspective of both the healthcare payer and facility. It conducted a cost-utility analysis and presented the results as an incremental cost-utility ratio (ICUR) using quality-adjusted life-years (QALY). Uncertainty was assessed through one-way sensitivity analysis. The ICUR from the healthcare payer’s perspective is 1,485,211 CZK/QALY, and from the healthcare facility’s perspective, it is 1,186,048 CZK/QALY. The study indicates that RARC is not cost-effective for healthcare payers. The cost-effectiveness of healthcare facilities depends on the value of the willingness-to-pay threshold.

Druh

D - Stať ve sborníku

CEP obor

—

OECD FORD obor

50602 - Public administration

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název statě ve sborníku

Lecture Notes in Computer Science

ISBN

978-3-031-64635-5

ISSN

2366-6323

e-ISSN

1611-3349

Počet stran výsledku

11

Strana od-do

3-13

Název nakladatele

Springer

Místo vydání

Cham

Místo konání akce

Gran Canaria

Datum konání akce

15. 7. 2024

Typ akce podle státní příslušnosti

WRD - Celosvětová akce

Kód UT WoS článku

001308622700001